Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 20/20 | 1.00 |
| ▸ | LATS2 | Q9NRM7 | 15/20 | 1.00 |
| ▸ | PRKCH | P24723 | 2/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.76 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.67 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.67 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26177090 | 0.92 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20574557 | 0.91 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20548215 | 0.89 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20574643 | 0.86 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL15644317 | 0.86 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL29650626 | 0.86 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20547848 | 0.83 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20573807 | 0.83 | LATS1 (0.78) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20548100 | 0.83 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD | |
| SCHEMBL20547807 | 0.83 | LATS1 (1.00) | LATS1LATS2PRKCHPRKCEPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621222-B | 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | claimed |
| US-20200131474-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-04-30 | — | — | US | claimed |
| US-20180344738-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS AG (CH) | 2018-12-06 | — | — | US | claimed |
| CN-114621222-B | 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3615537-B1 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| EP-4142879-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-11458138-B2 | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | NOVARTIS AG (CH) | 2022-10-04 | — | — | US | disclosed |
| WO-2021220132-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-20200131474-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-04-30 | — | — | US | disclosed |
| EP-3615537-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-20180344738-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS AG (CH) | 2018-12-06 | — | — | US | disclosed |
| WO-2018198077-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | B2M, EPAS1, LATS2 | LATS1 5/4885LATS2 3/4885PRKCH 1043/4885 |
| US-20200131474-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | B2M, EPAS1, LATS2 | LATS1 5/4885LATS2 3/4885PRKCH 1000/4885 |
| US-11458138-B2 | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCH 1778/4885 |
| US-20180344738-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCH 1778/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCH 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.